Using SIRT1 activators such as SRT1720, SRT1460, and SRT3025 was reported to effectively inhibit tumor growth in a xenograft model and to promote the survival of pancreatic cancer cells [45]. Here, SIRT1 is linked to familial pancreatic carcinoma.